Q-omics provides the consensus-scored FAM180B profile across patient tissues and cancer cell-line models. FAM180B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM180B is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, FAM180B RNA expression shows 12,407 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, BLCA, and TGCT as cancer lineages where FAM180B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM180B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM180B survival associations across molecular data types. FAM180B RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM180B RNA expression–survival associations across cancer types. High FAM180B expression shows unfavorable associations in KIRC and LGG, but favorable associations in HNSC, UCS, CHOL and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM180B RNA expression.
This table summarizes FAM180B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAM180B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM180B shows lower tumor expression in BLCA, THCA, COAD, HNSC, READ and STAD. The BLCA box plot shows higher FAM180B RNA expression in normal versus tumor tissue (log2 FC = −3.235, t-test p < 0.001).
This table shows molecular features associated with FAM180B in patient tissues and cancer cell lines. In patient samples, FAM180B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM180B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
